Protalix BioTherapeutics Community

As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%.

Key Takeaways Expansion of rare disease therapeutics and strategic partnerships support robust product pipeline growth, diversified revenue streams, and improved commercial momentum. Regulatory incentives and a cost-efficient production platform enhance margins, accelerate market entry, and strengthen long-term earnings potential.